Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Ionis Pharmaceuticals Advances as Barclays Upgrades Stock

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 7/2/2025, 11:32 am ET 5 min read
Ionis Pharmaceuticals Advances as Barclays Upgrades Stock Thumbnail

Ionis Pharmaceuticals Inc.’s stock surged by 7.56% following promising research results and an FDA designation reaffirming investor confidence.

Key Updates for Investors:

  • Significant growth in stock prices due to Barclays upgrading Ionis Pharmaceuticals to “Overweight,” with an increase in the price target to $57.
  • Promising interim Phase 1 results for salanersen by Ionis and Biogen, showing potential in treating spinal muscular atrophy (SMA) and leading to further studies.
  • Global Phase 3 REVEAL study initiation for Angelman syndrome treatment, ION582, aiming to enroll around 200 participants.
  • Dr. Richard Geary’s retirement and Dr. Holly Kordasiewicz’s appointment as the Chief Development Officer for Ionis signal a new strategic direction for leadership.

Candlestick Chart

Live Update At 11:32:09 EST: On Wednesday, July 02, 2025 Ionis Pharmaceuticals Inc. stock [NASDAQ: IONS] is trending up by 7.56%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Recent Financial Overview

The financial picture for Ionis Pharmaceuticals shows a story of contrasts and interest. With the recent price rise, it is apparent that financial markets are reacting positively to the news and developments at Ionis. Here’s a breakdown:

Despite a 1.1% rise in shares experienced after the Barclays upgrade, Ionis Pharmaceuticals Inc. has seen some struggles financially. Their revenue over the reporting period shows their income was $705M. However, operational financial statements reveal a significant net income loss of approximately $147M. Negatively affected earnings highlighted by a diluted EPS of -$0.93, signal challenging times for profit-generation. Even so, successful developments in clinical trials for potential treatments show room for optimism.

More Breaking News

Analyzing their key ratios, Ionis displays a low asset turnover and a hefty gross margin at 98.5, yet a negative return on equity, marked at -85.28, indicates inefficiencies or insufficient earnings compared to equity. A 0.34 total debt-to-equity signifies controlled leverage levels compared to their market cap. Furthermore, the quick ratio stands at 8.7, emphasizing short-term financial strength despite financial losses.

Investor Confidence on the Rise

The news that Barclays upgraded Ionis’s stock doubles as a respective validation of the company’s strategic achievements. The upgrade to “Overweight” with a revised target price of $57 indicates optimism in Ionis’s future. Such initiatives as their work on salanersen, promising SMA treatments, and the approval pathway for the Angelman syndrome treatment exhibit well-placed confidence.

Banking on these developments, Biogen’s partnership enhances reputation and trust in Ionis’s drug pipeline. Enthusiasm radiates through the stock market, signaling investor confidence in their trajectory toward regulatory approval and market expansion.

Competitive Pressures Alongside Internal Transitions

Amidst the firm’s innovations, Ionis endures shifts within its own leadership structure. Dr. Richard Geary’s retirement follows behind a successful tenure marked by championing six innovative drug approvals. It heartens investors to know his legacy will proceed under Dr. Holly Kordasiewicz, whose expertise in neurology stands poised to guide Ionis through complex neurological treatments. A new narrative emerges of Ionis adapting its leadership to the landscape of drug discovery challenges and industry trends.

Market Implications and Final Thoughts

At a recent closing price above $42, Ionis stocks are showing signs of upward movement fueled by worthwhile developments. The collaborative endeavor for salanersen, along with the launch of the REVEAL study reflect growing momentum to fulfill unmet medical needs. Positive interim trials serve as beacon lights steering Ionis’s sustained market presence.

The consolidation of these impactful studies, upgrades, and internal strategy shifts signals enhanced trader trust and future price momentum opportunities. As technological advancements and strategic alliances propel them toward breakthroughs, Ionis Pharmaceuticals appears entrenched in a wave of growth and innovation as evident by market responses. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.” This trading wisdom aligns with Ionis’s systematic approach and strategic steadiness in navigating market landscapes.

Upcoming financial performance will ultimately depend on trial progress, increasing pipeline prospects, and strategic leadership. However, the interplay of current dynamics suggest Ionis’s journey remains promising, captured by agreement across stock upgrades and an encouraging shareholder sentiment. With every innovative step, Ionis advances, aiming to turn research ambitions into clinical realities and market success stories.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications